Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples

Modern Pathology

Volumn 25, Issue 10, 2012, Pages 1333-1344

  Nuovo, Gerard J ^a   Garofalo, Michela ^a   Valeri, Nicola ^a   Roulstone, Vicki ^b   Volinia, Stefano ^a   Cohn, David E ^c   Phelps, Mitch ^d   Harrington, Kevin J ^b   Vile, Richard ^e   Melcher, Alan ^b   Galanis, Evanthia ^e   Sehl, Sarah ^f   Adair, Rob ^b   Scott, Karen ^b   Rose, Ailsa ^b   Toogood, Giles ^b   Coffey, Matthew C ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e MAYO CLINIC   (United States)

^f ONCOLYTICS BIOTECH INC   (Canada)

Author keywords

apoptosis; caspase 3; microRNA let 7d; PKR; Ras; reovirus

Indexed keywords

CASPASE 3; MICRORNA; MICRORNA LET 7D; REOVIRAL PROTEIN; SYNAPTOPHYSIN; TUBULIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOVIRUS; REOVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TROPISM; UPREGULATION; VIRUS GENOME; VIRUS INHIBITION;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MELANOMA; MICRORNAS; ONCOLYTIC VIROTHERAPY; ORTHOREOVIRUS, MAMMALIAN; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REOVIRIDAE INFECTIONS; SKIN NEOPLASMS;

EID: 84866974959     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.95     Document Type: Article

References (26)

1. Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-3362. (Pubitemid 28279509)
2. Comins C, Heinemann L, Harrington K, et al. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol) 2008;20:548-554.
3. Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010;28:641-649.
4. Yap TA, Brunetto A, Pandha H, et al. Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs 2008;17:1925-1935.
5. Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002;62:1696-1701. (Pubitemid 34408491)
6. Heinemann L, Simpson GR, Boxall A, et al. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011;11:221.
7. Alain T, Wong JF, Endersby R, et al. Reovirus decreases azoxymethane-induced aberrant crypt foci and colon cancer in a rodent model. Cancer Gene Ther 2007; 14:867-872. (Pubitemid 47402377)
8. Sei S, Mussio JK, Yang QE, et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 2009;8:47-61.
9. Kottke T, Thompson J, Diaz RM, et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 2009;15:561-569.
10. Heinemann L, Simpson GR, Annels NE, et al. The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol Ther 2010;18:2085-2093.
11. Kottke T, Hall G, Pulido J, et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 2010;120:1551-1560.
12. Pandha HS, Heinemann L, Simpson GR, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009;15:6158-6166.
13. Kawaguchi K, Etoh T, Suzuki K, et al. Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model. Int J Oncol 2010;37:1433-1438.
14. Park EH, Park EH, Cho IR, et al. CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway. Cancer Gene Ther 2010;17:307-314.
15. Norman KL, Hirasawa K, Yang AD, et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004;101:11099-11104. (Pubitemid 38989590)
16. Harrington KJ, Karapanagiotou EM, Roulstone V, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010;16:3067-3077.
17. Nuovo GJ. In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and co-localization of their putative targets. Methods 2010;52:307-315.
18. Nuovo GJ. The utility of in situ-based methodologies including in situ polymerase chain reaction for the diagnosis and study of viral infections. Hum Pathol 2007;38:1123-1136. (Pubitemid 47058170)
19. Bagasra O, Pomerantz RJ. In situ polymerase chain reaction and HIV-1. Clin Lab Med 1994;14:351-365. (Pubitemid 24197973)
20. Iliopoulos D, Rotem A, Struhl K. Inhibition of miR-193a expression by Max and RXRa activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res 2011;71:5144-5153.
21. Farsetta DL, Chandran K, Nibert ML. Transcriptional activities of reovirus RNA polymerase in recoated cores. Initiation and elongation are regulated by separate mechanisms. J Biol Chem 2000;275:39693-39701. (Pubitemid 32063124)
22. Parker JS, Broering TJ, Kim J, et al. Reovirus core protein m2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. J Virol 2002;76:4483-4496. (Pubitemid 34309584)
23. Prestwich RJ, Errington F, Steele LP, et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009;183: 4312-4321.
24. Torrisani J, Bournet B, du Rieu MC, et al. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009;20:831-844.
25. Yang X, Lin X, Zhong X, et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 2010;70: 9463-9472.
26. Garofalo M, Croce CM. microRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 2011;51:25-43.